Tanja de Gruijl heads the Immunotherapy and Immune-monitoring Lab at the VUmc Cancer Center in Amsterdam, where she has been appointed Professor of Translational Tumour Immunology and holds a Fenna Diemer Lindeboom Chair. She has over 20 years of experience in the field of tumour immunology and more than 160 publications to her name. Her research ranges from preclinical topics to immune-monitoring of Phase I-III clinical trials. Her main line of research is the in vivo targeting and modulation of dendritic cells (DC) through genetic targeting and local cytokine or TLR-L administration. Further topics of research include tumour-mediated immune suppression, control of DC differentiation, the effects of cytostatic drugs on DC development and functionality, and the immune potentiation of tumour-draining lymph nodes and the tumour microenvironment. Her research has been supported by fellowships and grants from the Netherlands Organization for Scientific Research (NWO) and the Royal Dutch Cancer Society (KWF) and she is a recipient of a competitive research award of the Prostate Cancer Foundation. She has managed and supervised the research that has led to the allogeneic DC vaccination platform of the VUmc spin-off company DCPrime BV, of which she is scientific advisor. She is a member of the Grant Review committee of the US-based Melanoma Research Alliance, a member of the scientific council of the Dutch Cancer Society, and currently chairs the Dutch Tumour Immunology Working Party.